

10/581471  
AP3 Rec'd PCT/PTO 1 JUN 2006

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		<i>Complete if Known</i>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(use as many sheets as necessary)</i>		Application Number	To Be Assigned
		Filing Date	Herewith
		First Named Inventor	Philip FAY
		Art Unit	To Be Assigned
		Examiner Name	To Be Assigned
Sheet	1	of	2
		Attorney Docket Number	
		176/61702	

## **U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code <sup>a</sup> (if known)			
1	US 5,859,204 A	01-12-1999	Lollar		
2	US 6,759,216 B1	07-06-2004	Lollar		
3	US 6,780,614	08-24-2004	Négrier et al.		
4	US 6,800,461	10-05-2004	Négrier et al.		
5	US 6,271,025	08-07-2001	Négrier et al.		
6	US 5,576,291	11-19-1996	Curtis et al.		
7	US 5,880,327	03-09-1999	Lubon et al.		
8	US 5,998,589	12-07-1999	Buettner et al.		
9	US 6,376,463	04-23-2002	Lollar		
10	US 6,593,291	07-15-2003	Green et al.		
11	US 6,599,724	07-29-2003	Mikaelsson et al.		
12	US 6,458,563	10-01-2002	Lollar		
13	US 6,770,744	08-03-2004	Lollar		
14	US 2004/0197815 A1	10-07-2004	Hauser et al.		
15	US 2003/0125232 A1	07-03-2003	Griffin et al.		
16	US 2003/0166536 A1	09-04-2003	Lollar et al.		
17	US 2004/0092442 A1	05-13-2004	Kaufman et al.		
18	US 2004/0147436 A1	07-29-2004	Kim et al.		

## **FOREIGN PATENT DOCUMENTS**

**\*EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at 222.uspto.gov or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

/Marsha Tsay/

12.10.08

10018321.1 ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MT/

10/581471

AP3 Rec'd PCT/PTO 01 JUN 2005

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				<i>Complete if Known</i>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(use as many sheets as necessary)</i>				Application Number	To Be Assigned
				Filing Date	Herewith
				First Named Inventor	Philip FAY
				Art Unit	To Be Assigned
				Examiner Name	To Be Assigned
Sheet	2	of	2	Attorney Docket Number	176/61702

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T <sup>2</sup>
	19	WAKABAYASHI et al., "Residues 110-126 in the Factor VIII Heavy Chain Contain a Ca2+ Binding Site Required for Cofactor Activity," <i>Blood</i> 102(11):542a (2003).			
	20	AMANO et al., "Mutation at either ARg336 or Arg562 in Factor VIII is Insufficient for Complete Resistance to Activated Protein C (APC)-Mediated Inactivation: Implications for the APC Resistance Test," <i>Thromb Haemost</i> 79:557-563 (1998).			
	21	SWAROOP et al., "Mutagenesis of Potential Immunoglobulin-Binding Protein-Binding Site Enhances Secretion of Coagulation Factor VIII," <i>J Biol Chem</i> 272(39):24121-24124 (1997).			
	22	WAKABAYAHII et al., "Factor VIII: E113A Represents a High Specific Activity Factor VIII Arising From a Single Point Mutation within the Ca2+ Binding Site," <i>Blood</i> 104(11):479a (2004).			
	23	WAKABAYASHI et al., "Residues 110-126 in the A1 Domain of Factor VIII Contain a Ca2+ Binding Site Required for Cofactor Activity," <i>J Biol Chem</i> 279(13):12677-12684 (2004).			
	24	SARAFANOV et al., "Cell Surface Heparan Sulfate Proteoglycans Participate in Factor VIII Catabolism Mediated by Low Density Lipoprotein Receptor-Related Protein," <i>J Biol Chem</i> 276(15):11970-11979 (2001).			
	25	LENTING et al., "The Sequence of Glu1811-Lys1818 of Human Blood Coagulation Factor VIII Comprises a Binding Site for Activated Factor IX," <i>J Biol Chem</i> 271(4):1935-1940 (1996).			
	26	GALE et al., "An Engineered Interdomain Disulfide Bond Stabilizes Human Blood Coagulation Factor VIIa," <i>J Thrombosis and Haemostasis</i> 1(9):1966-1971 (2003) (abstract only).			
	27	PIPE et al., "Characterization of a Genetically Engineered Inactivation-Resistant Coagulation Factor VIIa," <i>Proc Natl Acad Sci USA</i> 94:11851-11856 (1997).			
	28	LENTING et al., "The Life Cycle of Coagulation Factor VIII in View of Its Structure and Function," <i>Blood</i> 92(11):3983-3996 (1998)			
	29	HERNÁNDEZ (editor), "Factor VIII/von Willebrand Factor Complex in Hemophilia A Treatment Recent Findings, Emerging Major Role," <i>Journal of Hematology</i> 88(9):1-27 (2003).			

Examiner Signature	/Marsha Tsay/	Date Considered	12.10.08
--------------------	---------------	-----------------	----------

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.